ArticleNucleic acids research2026
A general strategy to enhance aptamer affinity by suppressing dissociation through symmetric assembly.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Aptamers are programmable molecular recognition elements with broad utility in diagnostics, therapeutics, and synthetic biology. However, many aptamers suffer from insufficient affinity due to rapid target dissociation, and no general strategy currently exists to overcome this limitation. Here, we report a symmetry-guided assembly approach that enhances aptamer affinity by suppressing the dissociation rate constant (koff). Three identical aptamer units are spatially organized into a flexible trivalent assembly to enable kinetic cooperativity through rapid rebinding. Applied to aptamers targeting SARS-CoV-2 spike (both trimeric and monomeric S1 subunit), VEGF165 (dimeric), and cardiac troponin I (monomeric), the resulting trimers exhibited dissociation constants (Kd) in the low pM range and koff values in the 10-6 s-1 range, over 100-fold improvements relative to monomers. In a serum-based VEGF165 assay, the trimeric aptamer improved detection sensitivity by 30-fold. This modular, chemistry-based strategy is applicable to existing aptamers and establishes dissociation suppression as a general principle for engineering ultrahigh-affinity aptamers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.